



Immunosciences Lab., Inc.

Rahim Karjoo, M.D. Medical Director

REFERRING PHYSICIAN

JAUQUELYN MCCANDLESS, M.D.
P.O. BOX 1868
HONOLULU, HI. 96727

Patient Name:

PARK-ALVAREZ, RUBEN

Patient I.D.:

D0808062002

Blood Drawn	Processed	Reported	ISL No.
07/18/06	07/20/06	08/03/06	200714

TEST

RESULTS NORMAL ABNORMAL

REFERENCE RANGE

UNITS

*** GLIADIN ANTIBODY TEST ***

IgG GLIADIN	4	0-50	ELISA
IgM GLIADIN	10	0-20	ELISA
IgA GLIADIN	9	0-20	ELISA

RESULT WAS VERIFIED BY REPEAT ANALYSIS.

*****PLEASE NOTE NEW REFERENCE RANGES*****

Coeliac Disease is a chronic nutritional disturbance of children and possibly adults, caused by improper absorption of fats resulting in malnutrition, distended abdomen, and diarrhea. It is suggested that Coeliac Disease is due to a deficient peptidase, which allows toxic metabolites of gluten to accumulate. This accumulation of gluten metabolites results in cellular damage and increased intestinal permeability with enhanced non-specific macromolecular absorption. Consequently, antibodies to wheat proteins, gluten, intrinsic factor and parietal cell cell antigens are found in such patients. Therefore, measurements of antibodies to purified wheat protein and alpha-gliadin, along with parietal cell and intrinsic factor antibodies, appear to be disease specific. However, these antibodies, at lower titers, have also been described in patients with other diarrheal illnesses including inflammatory bowel syndrome and Crohn's Disease. This may predict future development of atrophic gastritis and autoimmune pernicious anemia. Further testing for reticulin antibody using a section of tissue that has been pretreated with wheat protein and/or antigliadin antibodies of IgA class should be considered. These antibodies are found to be highly specific.

The performance characteristics of this test were established through validation by Immunosciences Laboratory, Inc., and no approval is required by the U.S. Food and Drug Administration (FDA). Immunosciences Laboratory, Inc. is regulated under the Clinical Laboratory Improvement Amendments of 1988 ("CLIA") as qualified to perform high complexity clinical testing.

CONTINUED ON NEXT PAGE